M. Aitmagambetova, G. Smagulova, Bekmukhambetov E.Zh., I. Kokhreidze, A. Tulyaeva, G. Bakytzhanov
{"title":"Results of Genetic Screening of Germinal Mutations in BRCA 1 And BRCA 2 Genes in Patients with Breast Cancer in the Aktobe Region of West Kazakhstan","authors":"M. Aitmagambetova, G. Smagulova, Bekmukhambetov E.Zh., I. Kokhreidze, A. Tulyaeva, G. Bakytzhanov","doi":"10.1177/0300891620914174","DOIUrl":null,"url":null,"abstract":"Introduction: Breast cancer (BC) is the most common malignant disease affecting women around the world. Clinically, the most important BC susceptibility genes are BRCA1 and BRCA2. The objective of our study was to establish the frequencies of 8 mutations in the BRCA1 genes (185delAG, 4153delA, 5382insC, 3819delGTAAA, 3875delGTCT, 300T> G (Cys61Gly), 2080delA mutations) and BRCA2 (6174delT mutation) in patients with BC in the Aktobe region of Western Kazakhstan. Materials and research methods: This study involved 300 women with a confirmed diagnosis of BC, who were observed at the Medical Center of the West Kazakhstan Medical University named after Marat Ospanov in the period 2018-2019. Prior to sampling the material (peripheral whole blood), patients received informed consent to conduct the study. Genotyping was carried out by real-time PCR using the Oncogenetics BRCA kit (NPO DNA Technology) according to the manufacturer's instructions. Results: A total of 300 patients were identified 3 cases. Patient No. 1, 31 years old, Asian race (kazakh), a mutation in the BRCA1 5382insC gene was detected, the hereditary history was burdened. Given the patient’s mutation (5382incS), a family history (father died of lung cancer, sibling died of ovarian cancer), work was done on genetic counseling for relatives (mother, brother, sisters and their adult children). Based on the analysis, we revealed a similar mutation of 5382incS in a sibling (42 years old) and his own daughter (17 years old), a second sibling (37 years old). Patient No. 2, 68 years old, Caucasian race, a mutation in the BRCA1 300T> G gene (Cys61Gly) was detected, the hereditary history is not burdened. Patient No. 3, 59 years old, Caucasian race, burdened by heredity. Also, given the patient’s mutation (5382incS), a family history (mother and grandmother died of BC), a study was conducted (daughters). According to the result of the analysis, we revealed a similar mutation of 5382incS in the daughter. Thus, the case presented shows the need for a large-scale, in-depth study of this population for further personification of treatment and prophylactic examination of patient families.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"177 1","pages":"37 - 37"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0300891620914174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Breast cancer (BC) is the most common malignant disease affecting women around the world. Clinically, the most important BC susceptibility genes are BRCA1 and BRCA2. The objective of our study was to establish the frequencies of 8 mutations in the BRCA1 genes (185delAG, 4153delA, 5382insC, 3819delGTAAA, 3875delGTCT, 300T> G (Cys61Gly), 2080delA mutations) and BRCA2 (6174delT mutation) in patients with BC in the Aktobe region of Western Kazakhstan. Materials and research methods: This study involved 300 women with a confirmed diagnosis of BC, who were observed at the Medical Center of the West Kazakhstan Medical University named after Marat Ospanov in the period 2018-2019. Prior to sampling the material (peripheral whole blood), patients received informed consent to conduct the study. Genotyping was carried out by real-time PCR using the Oncogenetics BRCA kit (NPO DNA Technology) according to the manufacturer's instructions. Results: A total of 300 patients were identified 3 cases. Patient No. 1, 31 years old, Asian race (kazakh), a mutation in the BRCA1 5382insC gene was detected, the hereditary history was burdened. Given the patient’s mutation (5382incS), a family history (father died of lung cancer, sibling died of ovarian cancer), work was done on genetic counseling for relatives (mother, brother, sisters and their adult children). Based on the analysis, we revealed a similar mutation of 5382incS in a sibling (42 years old) and his own daughter (17 years old), a second sibling (37 years old). Patient No. 2, 68 years old, Caucasian race, a mutation in the BRCA1 300T> G gene (Cys61Gly) was detected, the hereditary history is not burdened. Patient No. 3, 59 years old, Caucasian race, burdened by heredity. Also, given the patient’s mutation (5382incS), a family history (mother and grandmother died of BC), a study was conducted (daughters). According to the result of the analysis, we revealed a similar mutation of 5382incS in the daughter. Thus, the case presented shows the need for a large-scale, in-depth study of this population for further personification of treatment and prophylactic examination of patient families.
乳腺癌(BC)是影响世界各地妇女的最常见的恶性疾病。临床上,最重要的BC易感基因是BRCA1和BRCA2。本研究的目的是确定哈萨克斯坦西部阿克托别地区BC患者BRCA1基因(185delAG、4153delA、532insc、3819delGTAAA、3875delGTCT、300T> G (Cys61Gly)、2080delA突变)和BRCA2 (6174delT突变)的8种突变频率。材料和研究方法:本研究纳入了300名确诊为BC的女性,这些女性于2018-2019年在西哈萨克斯坦医科大学以马拉特·奥斯帕诺夫命名的医学中心观察。在取样材料(外周全血)之前,患者获得进行研究的知情同意。使用Oncogenetics BRCA试剂盒(NPO DNA Technology)根据制造商的说明,通过实时PCR进行基因分型。结果:共检出300例患者3例。患者1号,31岁,亚裔(哈萨克族),检测到BRCA1 5382基因突变,遗传史较重。考虑到患者的突变(5382incS),家族史(父亲死于肺癌,兄弟姐妹死于卵巢癌),研究人员为亲属(母亲、兄弟姐妹及其成年子女)进行了遗传咨询。根据分析,我们在一位兄弟姐妹(42岁)和他自己的女儿(17岁),另一位兄弟姐妹(37岁)中发现了类似的5382incS突变。患者2号,68岁,白种人,检测到BRCA1 300T> G基因突变(Cys61Gly),遗传史无负担。3号患者,59岁,白种人,遗传负担。此外,考虑到患者的突变(5382incS),家族史(母亲和祖母死于BC),对女儿进行了研究。根据分析结果,我们在女儿身上发现了一个类似的532incs突变。因此,该病例表明需要对这一人群进行大规模、深入的研究,以进一步人格化治疗和对患者家属进行预防性检查。